Brand
Call 24-hours a day Free consultation No Fees Unless we Win
Attorney Referrals And Co-Counsel
Offices in Raleigh, North Carolina, and Eastern North Carolina
Focused On Serving Your Needs
Our Attorneys

"UPDATE: To protect your safety during the coronavirus (COVID-19) crisis, we offer video conferencing, as well as telephone conferences, in place of face-to-face meetings. Please contact our office today to set up a remote consultation."

Bleeding Injury from Xarelto?

Bleeding injury from Xarelto? Call our North Carolina Products Liability attorneys to discuss. We handle drug injury claims everyday. Let us use our knowledge for you.

Xarelto (Rivaroxoaban) is a drug called a Direct Thrombin Inhibitor Anticoagulant and is used to reduce the risk of stroke and blood clots in people with a heart condition called atrial fibrillation. Unfortunately, this medication has some serious side effects if used to reduce blood clots in patients with coronary artery disease.

Serious and Life-threatening Side Effects of Xarelto, including:

  • Uncontrolled unexpected bleeding
  • Stomach bleeding
  • bruising
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis
  • Stroke
  • Peripheral Edema
  • headaches
  • Pain in wound areas

The anticoagulant has been used by millions of Americans to reduce the risk of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE) and other blood clot injuries. It has been prescribed to individuals with non-valvular atrial fibrillation, following knee and hip replacement surgery and to prevent recurrence of clots.

While all blood thinners carry a risk of internal bleeding, Xarelto appears to be associated with a much greater risk than the manufacturers indicated in warnings provided for consumers and the medical community. Essentially, as drug makers sold and marketed this drug, they failed to advise that a lack of a reversal agent could lead to an increase in an adverse reaction. The failure of the drug to live up to the marketing hype has resulted in lawsuits as it may be unreasonably dangerous and potentially defective without an effective reversal agent.

In 2011, the U.S. Food and Drug Administration (FDA) first approved Xarelto (Rivaroxoaban), indicated to reduce the risk of strokes, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and blood clots in patients who have undergone hip or knee replacement surgery. Despite at least three attempts, it has not been approved to reduce blood clots in patients with coronary artery disease.

Joe Tunstall leads our personal injury and products liability department from our Raleigh and Eastern NC offices. Give him a call to discuss your concerns about Xarelto.

Categories

Archives

FindLaw Network